Partner Article

Aesica to expand into global animal health arena

A NEWCASTLE based pharmaceutical manufacturer - which now turns over £90m a year - is planning to extend its presence in the animal health arena.

Animal health products and treatments account for 2.5 per cent of the global pharmaceutical manufacturing market and Aesica is predicting significant annual growth across this niche market.

Aesica is currently operating in this arena with a range of animal health products that are exclusively manufactured in the UK for a host of global customers.

The company is now looking to build upon the successful delivery of these contracts and increase its share of the market both in the UK and the US.

Lal Khan, Business Unit Director, API, Aesica says: “It’s Aesica’s vision to become the leading supplier of APIs and formulated products to the global pharmaceutical and biotechnology industry and to achieve this target we must continually strive to extend and enhance our service offering.

“The animal health market presents a tangible opportunity for growth and we are keen to consolidate and build upon our existing portfolio of clients in this marketplace.”

The US commands the largest global share of the overarching pharmaceutical market, and it also currently dominates the animal health market.

And as part of Aesica’s commitment to global expansion, the organisation is investing heavily in developing its US portfolio.

This was posted in Bdaily's Members' News section by Ruth Mitchell .